Security for brands, barriers to generics expected following EU court ruling
MLex: Brand name drugmakers now have more opportunities to secure extended exclusivity for their medicines throughout the European Union, thanks to a recent EU Court of Justice ruling in disputes over Supplementary Protection Certificates, or SPCs, for medicinal products in the EU.